Pharma Equity Group A/S (CPH:PEG)

Market Cap	184.13M
Revenue (ttm)	n/a
Net Income (ttm)	-30.81M
Shares Out	1.23B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,010,130
Average Volume	537,069
Open	0.147
Previous Close	0.151
Day's Range	0.147 - 0.150
52-Week Range	0.140 - 0.398
Beta	n/a
RSI	39.64
Earnings Date	Mar 20, 2025

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG